Podcast appearances and mentions of Lucia M Novak

  • 11PODCASTS
  • 19EPISODES
  • 53mAVG DURATION
  • ?INFREQUENT EPISODES
  • May 19, 2022LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about Lucia M Novak

Latest podcast episodes about Lucia M Novak

PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast
Lucia M. Novak, MSN, ANP-BC, BC-ADM - Building Skills for Clinical Practice: Optimizing Insulin Management and Personalizing Diabetes Care With Faster-Acting Formulations and Newer Options in Delivery Technology

PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast

Play Episode Listen Later May 19, 2022 57:49


Go online to PeerView.com/TZT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Insulin is often a necessary treatment for people with diabetes. Yet, knowing when to properly initiate and titrate insulin therapy in people with type 1 and type 2 diabetes is unfamiliar to many clinicians. In this activity, an expert discusses current guidance for incorporating individual preferences in insulin therapy in a variety of treatment regimens, models effective communication strategies in telehealth visits, and offers approaches to overcome common barriers to therapeutic inertia and engage patients to improve time in range and reduce postprandial glucose excursions. Upon completion of this activity, participants should be better able to: Incorporate newer options in mealtime insulin and the latest advances in technology to overcome barriers to insulin initiation, simplify insulin delivery and dosing, improve postprandial glucose (PPG) levels and time in range (TIR), and enhance the quality of life in patients with insulin-treated diabetes, Engage in patient-centered discussions across the interprofessional care team to optimize use of the latest advances in rapid acting insulin and insulin technology to support patient-centered diabetes care.

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Lucia M. Novak, MSN, ANP-BC, BC-ADM - Building Skills for Clinical Practice: Optimizing Insulin Management and Personalizing Diabetes Care With Faster-Acting Formulations and Newer Options in Delivery Technology

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later May 19, 2022 57:49


Go online to PeerView.com/TZT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Insulin is often a necessary treatment for people with diabetes. Yet, knowing when to properly initiate and titrate insulin therapy in people with type 1 and type 2 diabetes is unfamiliar to many clinicians. In this activity, an expert discusses current guidance for incorporating individual preferences in insulin therapy in a variety of treatment regimens, models effective communication strategies in telehealth visits, and offers approaches to overcome common barriers to therapeutic inertia and engage patients to improve time in range and reduce postprandial glucose excursions. Upon completion of this activity, participants should be better able to: Incorporate newer options in mealtime insulin and the latest advances in technology to overcome barriers to insulin initiation, simplify insulin delivery and dosing, improve postprandial glucose (PPG) levels and time in range (TIR), and enhance the quality of life in patients with insulin-treated diabetes, Engage in patient-centered discussions across the interprofessional care team to optimize use of the latest advances in rapid acting insulin and insulin technology to support patient-centered diabetes care.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Lucia M. Novak, MSN, ANP-BC, BC-ADM - Building Skills for Clinical Practice: Optimizing Insulin Management and Personalizing Diabetes Care With Faster-Acting Formulations and Newer Options in Delivery Technology

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 19, 2022 57:16


Go online to PeerView.com/TZT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Insulin is often a necessary treatment for people with diabetes. Yet, knowing when to properly initiate and titrate insulin therapy in people with type 1 and type 2 diabetes is unfamiliar to many clinicians. In this activity, an expert discusses current guidance for incorporating individual preferences in insulin therapy in a variety of treatment regimens, models effective communication strategies in telehealth visits, and offers approaches to overcome common barriers to therapeutic inertia and engage patients to improve time in range and reduce postprandial glucose excursions. Upon completion of this activity, participants should be better able to: Incorporate newer options in mealtime insulin and the latest advances in technology to overcome barriers to insulin initiation, simplify insulin delivery and dosing, improve postprandial glucose (PPG) levels and time in range (TIR), and enhance the quality of life in patients with insulin-treated diabetes, Engage in patient-centered discussions across the interprofessional care team to optimize use of the latest advances in rapid acting insulin and insulin technology to support patient-centered diabetes care.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Lucia M. Novak, MSN, ANP-BC, BC-ADM - Building Skills for Clinical Practice: Optimizing Insulin Management and Personalizing Diabetes Care With Faster-Acting Formulations and Newer Options in Delivery Technology

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later May 19, 2022 57:49


Go online to PeerView.com/TZT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Insulin is often a necessary treatment for people with diabetes. Yet, knowing when to properly initiate and titrate insulin therapy in people with type 1 and type 2 diabetes is unfamiliar to many clinicians. In this activity, an expert discusses current guidance for incorporating individual preferences in insulin therapy in a variety of treatment regimens, models effective communication strategies in telehealth visits, and offers approaches to overcome common barriers to therapeutic inertia and engage patients to improve time in range and reduce postprandial glucose excursions. Upon completion of this activity, participants should be better able to: Incorporate newer options in mealtime insulin and the latest advances in technology to overcome barriers to insulin initiation, simplify insulin delivery and dosing, improve postprandial glucose (PPG) levels and time in range (TIR), and enhance the quality of life in patients with insulin-treated diabetes, Engage in patient-centered discussions across the interprofessional care team to optimize use of the latest advances in rapid acting insulin and insulin technology to support patient-centered diabetes care.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Lucia M. Novak, MSN, ANP-BC, BC-ADM - Building Skills for Clinical Practice: Optimizing Insulin Management and Personalizing Diabetes Care With Faster-Acting Formulations and Newer Options in Delivery Technology

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 19, 2022 57:16


Go online to PeerView.com/TZT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Insulin is often a necessary treatment for people with diabetes. Yet, knowing when to properly initiate and titrate insulin therapy in people with type 1 and type 2 diabetes is unfamiliar to many clinicians. In this activity, an expert discusses current guidance for incorporating individual preferences in insulin therapy in a variety of treatment regimens, models effective communication strategies in telehealth visits, and offers approaches to overcome common barriers to therapeutic inertia and engage patients to improve time in range and reduce postprandial glucose excursions. Upon completion of this activity, participants should be better able to: Incorporate newer options in mealtime insulin and the latest advances in technology to overcome barriers to insulin initiation, simplify insulin delivery and dosing, improve postprandial glucose (PPG) levels and time in range (TIR), and enhance the quality of life in patients with insulin-treated diabetes, Engage in patient-centered discussions across the interprofessional care team to optimize use of the latest advances in rapid acting insulin and insulin technology to support patient-centered diabetes care.

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Lucia M. Novak, MSN, ANP-BC, BC-ADM - Building Skills for Clinical Practice: Optimizing Insulin Management and Personalizing Diabetes Care With Faster-Acting Formulations and Newer Options in Delivery Technology

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 19, 2022 57:16


Go online to PeerView.com/TZT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Insulin is often a necessary treatment for people with diabetes. Yet, knowing when to properly initiate and titrate insulin therapy in people with type 1 and type 2 diabetes is unfamiliar to many clinicians. In this activity, an expert discusses current guidance for incorporating individual preferences in insulin therapy in a variety of treatment regimens, models effective communication strategies in telehealth visits, and offers approaches to overcome common barriers to therapeutic inertia and engage patients to improve time in range and reduce postprandial glucose excursions. Upon completion of this activity, participants should be better able to: Incorporate newer options in mealtime insulin and the latest advances in technology to overcome barriers to insulin initiation, simplify insulin delivery and dosing, improve postprandial glucose (PPG) levels and time in range (TIR), and enhance the quality of life in patients with insulin-treated diabetes, Engage in patient-centered discussions across the interprofessional care team to optimize use of the latest advances in rapid acting insulin and insulin technology to support patient-centered diabetes care.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Lucia M. Novak, MSN, ANP-BC, BC-ADM - Building Skills for Clinical Practice: Optimizing Insulin Management and Personalizing Diabetes Care With Faster-Acting Formulations and Newer Options in Delivery Technology

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later May 19, 2022 57:49


Go online to PeerView.com/TZT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Insulin is often a necessary treatment for people with diabetes. Yet, knowing when to properly initiate and titrate insulin therapy in people with type 1 and type 2 diabetes is unfamiliar to many clinicians. In this activity, an expert discusses current guidance for incorporating individual preferences in insulin therapy in a variety of treatment regimens, models effective communication strategies in telehealth visits, and offers approaches to overcome common barriers to therapeutic inertia and engage patients to improve time in range and reduce postprandial glucose excursions. Upon completion of this activity, participants should be better able to: Incorporate newer options in mealtime insulin and the latest advances in technology to overcome barriers to insulin initiation, simplify insulin delivery and dosing, improve postprandial glucose (PPG) levels and time in range (TIR), and enhance the quality of life in patients with insulin-treated diabetes, Engage in patient-centered discussions across the interprofessional care team to optimize use of the latest advances in rapid acting insulin and insulin technology to support patient-centered diabetes care.

PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
Lucia M. Novak, MSN, ANP-BC, BC-ADM - Building Skills for Clinical Practice: Optimizing Insulin Management and Personalizing Diabetes Care With Faster-Acting Formulations and Newer Options in Delivery Technology

PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 19, 2022 57:16


Go online to PeerView.com/TZT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Insulin is often a necessary treatment for people with diabetes. Yet, knowing when to properly initiate and titrate insulin therapy in people with type 1 and type 2 diabetes is unfamiliar to many clinicians. In this activity, an expert discusses current guidance for incorporating individual preferences in insulin therapy in a variety of treatment regimens, models effective communication strategies in telehealth visits, and offers approaches to overcome common barriers to therapeutic inertia and engage patients to improve time in range and reduce postprandial glucose excursions. Upon completion of this activity, participants should be better able to: Incorporate newer options in mealtime insulin and the latest advances in technology to overcome barriers to insulin initiation, simplify insulin delivery and dosing, improve postprandial glucose (PPG) levels and time in range (TIR), and enhance the quality of life in patients with insulin-treated diabetes, Engage in patient-centered discussions across the interprofessional care team to optimize use of the latest advances in rapid acting insulin and insulin technology to support patient-centered diabetes care.

The NACE Clinical Highlights Show
Optimizing Outcomes in Diabetes With GLP-1 Therapy

The NACE Clinical Highlights Show

Play Episode Listen Later May 31, 2020 25:38


In this episode, host Dr. Gregg Sherman and NACE expert faculty member, Lucia M. Novak, MSN, ANP-BC. BC-ADM, discuss Optimizing Outcomes in Diabetes With GLP-1 Therapy. Dr. Sherman and Ms. Novak discuss the glycemic and cardiorenal effects of GLP-1 RAs, the differences between injectable and oral GLP-1 RA formulations, and strategies for integrating GLP-1 RA therapy into earlier therapeutic decision-making, based on the newest treatment. About Lucia M. Novak, MSN, ANP-BC. BC-ADMPresident and Owner, Diabetes Consulting Services, Rockville, MDDiabetes Expert, Diabetes & Endocrine Associates, Silver Spring, MDMs. Novak is a board-certified nurse practitioner in both Adult Health and Advanced Diabetes Management and has over 17 years of clinical, research and educational experience in diabetes mellitus. Ms. Novak has provided her expertise pertaining to diabetes as a Contributing Author for the Lippincott Manual of Nursing Practice for the last 4 editions and is also a Contributing Author for the 1st edition of Genomic Essentials for Graduate Level Nurses. Ms. Novak serves as an Associate Editor for Clinical Diabetes. Ms. Novak has been repeatedly recognized for her outstanding contributions as a clinician, researcher and educator. In 2015, she was designated Master Clinician for her proven leadership and clinical prowess, an accolade that placed her among the top 2% of the health care providers of the Walter Reed National Military Medical Center and is also a recipient of The DAISY Foundation Award for Extraordinary Nurses. Her nearly 28 years of nursing experience include active duty service as a Commissioned Officer of the United States Army Nurse Corps. This podcast episode  is supported by an  independent medical education grant from Novo Nordisk.  This activity is not certified for CME/CE credit.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Lucia M. Novak, MSN, ANP-BC, BC-ADM, CDTC - The Art of Medicine: Creating Treatment Regimens With GLP-1 RAs to Reduce Cardiovascular Risks in Patients With T2DM

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 1, 1970 51:18


Go online to PeerView.com/SVU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) describes shared decision-making strategies to individualize treatment and reduce cardiovascular risks in patients with T2DM using GLP-1 receptor agonists (GLP-1 RAs). Upon completion of this activity, participants should be better able to: Review the role of, current guidance, and approved indications for GLP-1 RAs in the management of T2DM, Describe the difference between primary and secondary prevention of cardiovascular events and the mechanism(s) proposed for GLP-1 RAs that may reduce cardiovascular risks in patients with T2DM, Evaluate the benefits and risks of GLP-1 RAs based on results from recent clinical trials, especially in terms of primary and secondary cardiovascular prevention, Integrate GLP-1 RAs, as appropriate and using shared decision-making, into the care of patients with T2DM.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Lucia M. Novak, MSN, ANP-BC, BC-ADM, CDTC - The Art of Medicine: Creating Treatment Regimens With GLP-1 RAs to Reduce Cardiovascular Risks in Patients With T2DM

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Jan 1, 1970 53:02


Go online to PeerView.com/SVU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) describes shared decision-making strategies to individualize treatment and reduce cardiovascular risks in patients with T2DM using GLP-1 receptor agonists (GLP-1 RAs). Upon completion of this activity, participants should be better able to: Review the role of, current guidance, and approved indications for GLP-1 RAs in the management of T2DM, Describe the difference between primary and secondary prevention of cardiovascular events and the mechanism(s) proposed for GLP-1 RAs that may reduce cardiovascular risks in patients with T2DM, Evaluate the benefits and risks of GLP-1 RAs based on results from recent clinical trials, especially in terms of primary and secondary cardiovascular prevention, Integrate GLP-1 RAs, as appropriate and using shared decision-making, into the care of patients with T2DM.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Lucia M. Novak, MSN, ANP-BC, BC-ADM, CDTC - The Art of Medicine: Creating Treatment Regimens With GLP-1 RAs to Reduce Cardiovascular Risks in Patients With T2DM

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 1, 1970 51:18


Go online to PeerView.com/SVU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) describes shared decision-making strategies to individualize treatment and reduce cardiovascular risks in patients with T2DM using GLP-1 receptor agonists (GLP-1 RAs). Upon completion of this activity, participants should be better able to: Review the role of, current guidance, and approved indications for GLP-1 RAs in the management of T2DM, Describe the difference between primary and secondary prevention of cardiovascular events and the mechanism(s) proposed for GLP-1 RAs that may reduce cardiovascular risks in patients with T2DM, Evaluate the benefits and risks of GLP-1 RAs based on results from recent clinical trials, especially in terms of primary and secondary cardiovascular prevention, Integrate GLP-1 RAs, as appropriate and using shared decision-making, into the care of patients with T2DM.

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Lucia M. Novak, MSN, ANP-BC, BC-ADM, CDTC - The Art of Medicine: Creating Treatment Regimens With GLP-1 RAs to Reduce Cardiovascular Risks in Patients With T2DM

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 1, 1970 53:02


Go online to PeerView.com/SVU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) describes shared decision-making strategies to individualize treatment and reduce cardiovascular risks in patients with T2DM using GLP-1 receptor agonists (GLP-1 RAs). Upon completion of this activity, participants should be better able to: Review the role of, current guidance, and approved indications for GLP-1 RAs in the management of T2DM, Describe the difference between primary and secondary prevention of cardiovascular events and the mechanism(s) proposed for GLP-1 RAs that may reduce cardiovascular risks in patients with T2DM, Evaluate the benefits and risks of GLP-1 RAs based on results from recent clinical trials, especially in terms of primary and secondary cardiovascular prevention, Integrate GLP-1 RAs, as appropriate and using shared decision-making, into the care of patients with T2DM.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Lucia M. Novak, MSN, ANP-BC, BC-ADM, CDTC - The Art of Medicine: Creating Treatment Regimens With GLP-1 RAs to Reduce Cardiovascular Risks in Patients With T2DM

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 1, 1970 51:18


Go online to PeerView.com/SVU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) describes shared decision-making strategies to individualize treatment and reduce cardiovascular risks in patients with T2DM using GLP-1 receptor agonists (GLP-1 RAs). Upon completion of this activity, participants should be better able to: Review the role of, current guidance, and approved indications for GLP-1 RAs in the management of T2DM, Describe the difference between primary and secondary prevention of cardiovascular events and the mechanism(s) proposed for GLP-1 RAs that may reduce cardiovascular risks in patients with T2DM, Evaluate the benefits and risks of GLP-1 RAs based on results from recent clinical trials, especially in terms of primary and secondary cardiovascular prevention, Integrate GLP-1 RAs, as appropriate and using shared decision-making, into the care of patients with T2DM.

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Lucia M. Novak, MSN, ANP-BC, BC-ADM, CDTC - The Art of Medicine: Creating Treatment Regimens With GLP-1 RAs to Reduce Cardiovascular Risks in Patients With T2DM

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 1, 1970 53:02


Go online to PeerView.com/SVU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) describes shared decision-making strategies to individualize treatment and reduce cardiovascular risks in patients with T2DM using GLP-1 receptor agonists (GLP-1 RAs). Upon completion of this activity, participants should be better able to: Review the role of, current guidance, and approved indications for GLP-1 RAs in the management of T2DM, Describe the difference between primary and secondary prevention of cardiovascular events and the mechanism(s) proposed for GLP-1 RAs that may reduce cardiovascular risks in patients with T2DM, Evaluate the benefits and risks of GLP-1 RAs based on results from recent clinical trials, especially in terms of primary and secondary cardiovascular prevention, Integrate GLP-1 RAs, as appropriate and using shared decision-making, into the care of patients with T2DM.

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Lucia M. Novak, MSN, ANP-BC, BC-ADM, CDTC - The Art of Medicine: Creating Treatment Regimens With GLP-1 RAs to Reduce Cardiovascular Risks in Patients With T2DM

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 1, 1970 51:18


Go online to PeerView.com/SVU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) describes shared decision-making strategies to individualize treatment and reduce cardiovascular risks in patients with T2DM using GLP-1 receptor agonists (GLP-1 RAs). Upon completion of this activity, participants should be better able to: Review the role of, current guidance, and approved indications for GLP-1 RAs in the management of T2DM, Describe the difference between primary and secondary prevention of cardiovascular events and the mechanism(s) proposed for GLP-1 RAs that may reduce cardiovascular risks in patients with T2DM, Evaluate the benefits and risks of GLP-1 RAs based on results from recent clinical trials, especially in terms of primary and secondary cardiovascular prevention, Integrate GLP-1 RAs, as appropriate and using shared decision-making, into the care of patients with T2DM.

PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast
Lucia M. Novak, MSN, ANP-BC, BC-ADM, CDTC - The Art of Medicine: Creating Treatment Regimens With GLP-1 RAs to Reduce Cardiovascular Risks in Patients With T2DM

PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 1, 1970 53:02


Go online to PeerView.com/SVU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) describes shared decision-making strategies to individualize treatment and reduce cardiovascular risks in patients with T2DM using GLP-1 receptor agonists (GLP-1 RAs). Upon completion of this activity, participants should be better able to: Review the role of, current guidance, and approved indications for GLP-1 RAs in the management of T2DM, Describe the difference between primary and secondary prevention of cardiovascular events and the mechanism(s) proposed for GLP-1 RAs that may reduce cardiovascular risks in patients with T2DM, Evaluate the benefits and risks of GLP-1 RAs based on results from recent clinical trials, especially in terms of primary and secondary cardiovascular prevention, Integrate GLP-1 RAs, as appropriate and using shared decision-making, into the care of patients with T2DM.

PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
Lucia M. Novak, MSN, ANP-BC, BC-ADM, CDTC - The Art of Medicine: Creating Treatment Regimens With GLP-1 RAs to Reduce Cardiovascular Risks in Patients With T2DM

PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 1, 1970 51:18


Go online to PeerView.com/SVU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) describes shared decision-making strategies to individualize treatment and reduce cardiovascular risks in patients with T2DM using GLP-1 receptor agonists (GLP-1 RAs). Upon completion of this activity, participants should be better able to: Review the role of, current guidance, and approved indications for GLP-1 RAs in the management of T2DM, Describe the difference between primary and secondary prevention of cardiovascular events and the mechanism(s) proposed for GLP-1 RAs that may reduce cardiovascular risks in patients with T2DM, Evaluate the benefits and risks of GLP-1 RAs based on results from recent clinical trials, especially in terms of primary and secondary cardiovascular prevention, Integrate GLP-1 RAs, as appropriate and using shared decision-making, into the care of patients with T2DM.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Lucia M. Novak, MSN, ANP-BC, BC-ADM, CDTC - The Art of Medicine: Creating Treatment Regimens With GLP-1 RAs to Reduce Cardiovascular Risks in Patients With T2DM

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 1, 1970 53:02


Go online to PeerView.com/SVU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) describes shared decision-making strategies to individualize treatment and reduce cardiovascular risks in patients with T2DM using GLP-1 receptor agonists (GLP-1 RAs). Upon completion of this activity, participants should be better able to: Review the role of, current guidance, and approved indications for GLP-1 RAs in the management of T2DM, Describe the difference between primary and secondary prevention of cardiovascular events and the mechanism(s) proposed for GLP-1 RAs that may reduce cardiovascular risks in patients with T2DM, Evaluate the benefits and risks of GLP-1 RAs based on results from recent clinical trials, especially in terms of primary and secondary cardiovascular prevention, Integrate GLP-1 RAs, as appropriate and using shared decision-making, into the care of patients with T2DM.